On April 27, 2023 LamKap Bio reported that it has presented data on NILK-2301, NILK-2401 & NILK-3301 (Press release, LamKap Bio Group, APR 27, 2023, View Source [SID1234630610]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The American Association for Cancer Research (AACR) (Free AACR Whitepaper) hosted the AACR (Free AACR Whitepaper) annual meeting 2023 April 14-19, 2023. LamKap Bio is very pleased to have presented preclinical data on the combination of NILK-2301 (CEACAM5xCD3) and NILK-2401 (CEACAM5xCD47) as well as NILK-2301 and NILK-3301 (CEACAM5xCD28) bispecific antibodies for immunotherapy of patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) expressing solid tumors.

"Combination of κλ bispecific antibodies targeting innate (CEAxCD47, NILK-2401) and adaptive immunity (CEAxCD3, NILK-2301 and CEAxCD28, NILK-3301) for next generation immunotherapy of CEA-expressing cancers" (abstract no. 5100) was presented on site in poster section 22 (board no. 3) on April 18, 1:30 PM – 5:00 PM.